Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate

The Outcome of Congenital Cytomegalovirus Infection in Relation to Maternal Antibody Status

1992 • 1,071 citations

Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis

1994 • 750 citations

Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease

1991 • 686 citations

The Cytomegaloviruses: Ubiquitous Agents with Protean Clinical Manifestations

1971 • 649 citations

NYVAC: A highly attenuated strain of vaccinia virus

1992 • 473 citations

Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.

1986 • 334 citations

Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response

1990 • 316 citations

Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses.

1988 • 255 citations

Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression.

1991 • 235 citations

Immunisation with canarypox virus expressing rabies glycoprotein

1992 • 184 citations

Nonreplicating viral vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins

1992 • 154 citations

Antibodies to Recombinant-Derived Glycoprotein B after Natural Human Cytomegalovirus Infection Correlate with Neutralizing Activity

1992 • 154 citations

Cloning and expression of foreign genes in vaccinia virus, using a host range selection system

1989 • 151 citations

Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL

1993 • 114 citations

Potential use of non-replicating vectors as recombinant vaccines

1992 • 110 citations

Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB)

1988 • 106 citations

Induction of Cytotoxic T Lymphocytes by Recombinant Canarypox (ALVAC) and Attenuated Vaccinia (NYVAC) Viruses Expressing the HIV-1 Envelope Glycoprotein

1993 • 97 citations

Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination

1993 • 93 citations

Highly Attenuated Poxvirus Vectors

1992 • 89 citations

Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers

1990 • 79 citations

Immune responses to isolated human cytomegalovirus envelope proteins

1986 • 54 citations

A rapid microneutralization assay for cytomegalovirus

1986 • 54 citations

High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity

1991 • 50 citations

Immune Response to Human Cytomegalovirus Infection

1990 • 49 citations

An Adenovirus Recombinant that Expresses the Human Cytomegalovirus Major Envelope Glycoprotein and Induces Neutralizing Antibodies

1990 • 48 citations

The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B- and T-cell immune responses in humans

1991 • 36 citations

Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB

1993 • 26 citations

Human Cytomegalovirus and Atherogenesis

1993 • 7 citations